Physician profile
Sarah Eley
NPI 1235832049
$2,561.77
in general payments reported to CMS, 2019-2025
14 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $620 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $743.27 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $304.11 | 2024-2025 | |
| Ucb, INC. | $257.15 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $164.68 | 2025 | Dupixent |
| Pfizer INC. | $158.86 | 2024-2025 | |
| Abbvie INC. | $151.93 | 2025 | |
| Incyte Corporation | $124.36 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.99 | 2024 | Spevigo |
| Organon LLC | $116.06 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $101.09 | 2024 | Sotyktu |
| Mallinckrodt Hospital Products INC. | $97.71 | 2025 | Acthar |
| Kyowa Kirin, INC. | $91.56 | 2024 | Poteligeo |
| Galderma Laboratories, L.P. | $89.28 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $37.72 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Eley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.